PMC:7212965 / 47456-48041 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T129","span":{"begin":240,"end":259},"obj":"Chemical"},{"id":"T130","span":{"begin":240,"end":249},"obj":"Chemical"},{"id":"T131","span":{"begin":250,"end":259},"obj":"Chemical"},{"id":"T132","span":{"begin":325,"end":336},"obj":"Chemical"},{"id":"T133","span":{"begin":341,"end":351},"obj":"Chemical"}],"attributes":[{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_134722"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Limitations of Current Evidence on Treatment-Related Adverse Effects\nMost of the information regarding Gl adverse events come from indirect evidence from medications that are FDA-approved for other indications, such as the chloroquines and lopinavir/ritonavir. In particular, Gl adverse events are poorly understood for both favipiravir and remdesivir, including the frequency and severity of aminotransferase elevations and incidence of Gl manifestations. As ongoing clinical trials are completed regarding efficacy of therapy, additional data regarding Gl adverse events will emerge."}

{"project":"LitCovid-sentences","denotations":[{"id":"T317","span":{"begin":0,"end":68},"obj":"Sentence"},{"id":"T318","span":{"begin":69,"end":260},"obj":"Sentence"},{"id":"T319","span":{"begin":261,"end":456},"obj":"Sentence"},{"id":"T320","span":{"begin":457,"end":585},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Limitations of Current Evidence on Treatment-Related Adverse Effects\nMost of the information regarding Gl adverse events come from indirect evidence from medications that are FDA-approved for other indications, such as the chloroquines and lopinavir/ritonavir. In particular, Gl adverse events are poorly understood for both favipiravir and remdesivir, including the frequency and severity of aminotransferase elevations and incidence of Gl manifestations. As ongoing clinical trials are completed regarding efficacy of therapy, additional data regarding Gl adverse events will emerge."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1284","span":{"begin":223,"end":235},"obj":"Chemical"},{"id":"1285","span":{"begin":240,"end":259},"obj":"Chemical"},{"id":"1286","span":{"begin":325,"end":336},"obj":"Chemical"},{"id":"1287","span":{"begin":341,"end":351},"obj":"Chemical"}],"attributes":[{"id":"A1284","pred":"tao:has_database_id","subj":"1284","obj":"MESH:D002738"},{"id":"A1285","pred":"tao:has_database_id","subj":"1285","obj":"MESH:C558899"},{"id":"A1286","pred":"tao:has_database_id","subj":"1286","obj":"MESH:C462182"},{"id":"A1287","pred":"tao:has_database_id","subj":"1287","obj":"MESH:C000606551"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Limitations of Current Evidence on Treatment-Related Adverse Effects\nMost of the information regarding Gl adverse events come from indirect evidence from medications that are FDA-approved for other indications, such as the chloroquines and lopinavir/ritonavir. In particular, Gl adverse events are poorly understood for both favipiravir and remdesivir, including the frequency and severity of aminotransferase elevations and incidence of Gl manifestations. As ongoing clinical trials are completed regarding efficacy of therapy, additional data regarding Gl adverse events will emerge."}